Skip to main content
Publications
Anthony MS, Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B, Beachler DC, Crowe CL, Johannes CB, Juhaeri J, Lanes S, Pan C, Rothman KJ, Saltus CW, Walsh KE. Risk of anaphylaxis among new users of glp-1 receptor agonists: a cohort study. Diabetes Care. 2024 Apr 1;47(4):712-9. doi: 10.2337/dc23-1911
Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Michel A, Latocha M, Schmidt-Ott UM, Lovic N, Brunck LR, Johnson KT, Suzart-Woischnik K. Evaluation of physician knowledge of safety and safe use information for intravitreal aflibercept injection in Europe: a second survey of physicians following dissemination of updated risk-minimization materials. Pharmaceut Med. 2024 Jan;38(1):63-73. doi: 10.1007/s40290-023-00506-7
Dong OM, Roberts MC, Wu RR, Voils CI, Sperber N, Gavin KL, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Chapman JG, Voora D. Evaluation of the veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program at initial test sites. Pharmacogenomics. 2021 Nov 1;22(17):1121-33. doi: 10.2217/pgs-2021-0089
Dong OM, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Meyer LJ, Icardi M, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Jacobitz R, Rozelle S, Chapman JG, Voora D. Institutional profile: veterans affairs pharmacogenomic testing for veterans (PHASER) program. Pharmacogenomics. 2021 Jan 6;22(3):2020-0173. doi: 10.2217/pgs-2020-0173
Pladevall-Vila M, Singal B, Williams LK, Brotons C, Guyer H, Sadurni J, Falces C, Serrano-Rios M, Gabriel R, Shaw JE, Zimmet PZ, Haffner S. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care. 2006 Jan;29(1):113-22.